Pursuant to the provisions of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (‘Listing Regulations’), Cipla has informed that the Company has entered into a marketing and distribution agreement with Eli Lilly and Company (India) (referred as ‘Lilly’) for launch of second brand of Tirzepatide in India. The details required to be disclosed under the Listing Regulations read with SEBI Circular no. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11th November, 2024 on Lilly and Cipla sign marketing and distribution agreement for second brand of Tirzepatide in India are enclosed to this intimation as Annexure I. A copy of the press release pertaining to the said product launch is enclosed as Annexure II.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1807.25 |
| Dr. Reddys Lab | 1287.50 |
| Cipla | 1378.00 |
| Zydus Lifesciences | 1104.55 |
| Lupin | 2282.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: